fda safety communication semaglutide naion 2025 GLP-1 Receptor Agonists and vision risk The FDA sent a warning

March 2024: Litigation was still in the early stages

For example, in head-to-head trials, patients on the highest dose of Zepbound lost up to 22.5% of their body weight over 72 weeks, while those taking semaglutide GLP-1 (Wegovy) lost about 15% over a similar period

Oral semaglutide tablets Youll take oral semaglutide tablets, including Wegovy and Rybelsus, once per day

Studies suggest patients taking these medications can lose 15% to 20% of their body weight, on average

People who should take extra caution before taking semaglutide include: 2 Have a history of thyroid cancer Are allergic to semaglutide Have severe gastrointestinal disorders Are under 18 years of age Have kidney or pancreatic problems Pregnant and breastfeeding parents This is not a complete list of warnings and precautions associated with semaglutide